Vedolizumab Anti-TNF agents Small molecules Disability CARCINOGENESIS Endoscopic treatment Crohn’s disease Algorithm Thérapie ciblée Cancer Clinical trial Methylation Surgery Stricture Therapeutics Inflammatory Bowel Diseases Clinical guidelines Cell adhesion Inhibitor MORTALITY Colonic epithelial primary cells Ulcerative colitis Consensus Screening MARKER Dysbiosis Original Article Clinical Immune cells Ustekinumab Inflammatory bowel disease Colectomy MALT IL12 DNA METHYLATION Resistance Rituximab plus chlorambucil Colon cancer Primary sclerosing cholangitis Disease progression Genes MICROBIOTA Heart disease risk factors Intestinal crypts Neoadjuvant chemotherapy Résistance Gene expression Dysbiose Anti-TNF Méthylation Kidney diseases DNA methylation Microbiota Inflammatory bowel diseases Crohn's disease Monitoring Over 80s Biologics Patient-reported outcome Venous thromboembolism Gènes Safety Bacteria COLON-CANCER Maintenance therapy Drug IL23 Microbiote Parvimonas micra Rituximab T1118 translocation 18 FDG-PET/CT Bactéries Upper gastrointestinal tract Disease Progression HIV Tailored therapy Epigénétiques Colon Gene methylation Immunosuppressant Alkylating agents RISK Patients experience Fecal microbiota Survival Cost effectiveness Biomarker Eradication Tuberculosis Eligibility Effectiveness Helicobacter pylori Colorectal cancer Colibactin and lipids Acceptability Colorectal cancer Contraindication Inclusion PCR Epigenetics IBD